AEI’s Roger Bate Says Changes In Donor Policies Could Result In Inferior TB Medicines, Poor Patient Outcomes

AEI’s “AEIdeas”: Tuberculosis rates may rise due to inferior treatment
Roger Bate, visiting scholar at AEI, discusses the potential impact of changes in donor policies, particularly shifting from global to national purchase of TB drugs, on drug quality and patient outcomes. Bate notes, “The temptation to favor local producers with tariffs or quotas on imports starts as local companies cannot hope to compete. And as donors now start to pull back from nations and programs, local companies are likely to win business since they employ people and pay taxes locally. But the outcome for TB patients, and possibly malaria and HIV patients, is not a good one. Expect quality to go down and price to go up” (10/29).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.